Will escalating spending on HIV treatment displace funding for treatment of other diseases?

South African Medical Journal

Volumn 100, Issue 1, 2010, Pages 32-34

  Fleischer, Theodore ^a   Kevany, Sebastian ^b   Benatar, Solomon R ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BUDGET; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EDITORIAL; FUNDING; GOVERNMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NATIONAL HEALTH INSURANCE; PUBLIC HEALTH; SOUTH AFRICA;

FINANCING, ORGANIZED; HEALTH CARE RATIONING; HEALTH EXPENDITURES; HEALTH PRIORITIES; HIV INFECTIONS; HUMANS; SOUTH AFRICA;

EID: 75649108229     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Philip R. Hospital hell. Sunday Times 2009; 24 May.
2. Mukotsanjera V, Mwenge K, Giya G. HIV and AIDS Analysis of the South African National Budget (2009/10). Cape Town: Institute for Democracy in South Africa, 2009.
3. PriceWaterHouse Coopers. Weathering the storm: Budget 2009. http://www.pwc.com/za/ eng/pdf/pwc-Budget2009-summary.pdf (accessed 15 June 2009).
4. National Department of Health. HIV & AIDS and STI Strategic Plan for South Africa 2007-2011. National Department of health document. 2007. http://www.info.gov.za/ otherdocs/2007/aidsplan07.pdf (accessed 27 February 2009).
5. Ndlovu N. Funds running out for ARVs. Mail & Guardian 2009; 3 April.
6. Cullinan K. Zim crisis 'A threat to SA AIDS success'. Cape Times 2009; 4 April.
7. Blecher M, Thomas S. Health care financing. In: South African Health Review 2003/04. Durban: Health Systems Trust, 2005. http://www.hst.org.za/ publications/423 (accessed 27 February 2009).
8. England R. Are we spending too much on HIV? BMJ 2007; 334: 344.
9. Badri M. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 2006; 3(1): 0048-0056.
10. Nattrass N, Geffen N. The impact of reduced drug prices on the cost-effectiveness of HAART in South Africa. African Journal of AIDS Research 2005; 4(1): 65-67.
11. Houston S. Justice and HIV care in Africa - antiretrovirals in perspective. Journal of the International Association of Physicians in AIDS Care 2002; 1(2): 46-50.
12. Thom A, Cullinan K. Children 'forgotten' in antiretroviral roll-out. Cape Times 2005; 6 June.
13. See also, Reynolds L, Sanders D. Our children are dying in droves. Cape Times 2007; 22 August.
14. Shiffman J. Has donor prioritization of HIV/AIDS displaced aid for other health issues? Health Policy Plan 2008; 23: 95-100.
15. De Lay P, Greener R, Izazola JA. Are we spending too much on HIV? BMJ 2007; 334: 345.
16. Yu D, Souteyrand Y, Banda MA, Kaufman J, Perriëns JH. Investment in HIV/AIDS programs: Does it help strengthen health systems in developing countries? Globalization and Health 2008; doi: 10.1186/144-8603-4-8.
17. Smith A. Experts want African aid funds channelled away from HIV. The Observer 2009; 25 October.
18. Marseille E, Hoffman P, Kahn JG. HIV prevention before HAART in Sub-Saharan Africa. Lancet 2002; 359: 1851-1856.
19. Cairncross L. Hospitals forced to save money instead of lives. Cape Times 2007; 28 May.
20. The Times. State counts on private health facilities. The Times 2009; 6 June.
21. Broomberg J. Health reform must not destroy private sector. Cape Times 2009; 2 June.
22. Daniels N. Accountability for reasonableness: establishing fair process for priority setting is easier than agreeing on principles. BMJ 2000; 321: 1300-1301.
23. Benatar SR. Meeting infinite demands with finite means. Cape Times 2008; 24 June.
24. El-Sadr W, Abrams E. Scale-up of HIV care and treatment: Can it transform healthcare services in resource-limited settings? AIDS 2007; 21: suppl 5, S65-70.
25. Benatar SR, Gill S, Bakker I. Making progress in global health: the need for new paradigms. International Affairs 2009; 85(2): 347-371.